Clinical details for the different patient groups defined by dose prescribed to the 50% isodose
| Group | Number of tumours | Time period | Dose range (Gy) | Mean (SD) dose (Gy) | Mean number of isocentres | Tumour volume cm3 | Follow up in months mean (SD: range) |
|---|---|---|---|---|---|---|---|
| With experience, dose reduction was undertaken to decrease cranial nerve complications. At the same time patient selection evolved with smaller tumours being treated, and planning became more sophisticated, more isocentres being used. Overall, the median follow up for all patients was 51 months. | |||||||
| 1 | 13 | 1986–87 | 25 | 25 (0) | 1.5 (0.7) | 12.2 (16.7) | 82 (59: 4–136) |
| 2 | 17 | 1988–94 | 17.5–20 | 17.8 (0.8) | 1.7 (1.0) | 3.8 (4.0) | 89 (48: 9–154) |
| 3 | 92 | From 1993 | 10–16 | 13.4 (1.6) | 5.4 (2.5) | 4.6 (4.3) | 38 (23: 6–89) |
| Overall | 122 | 1986–2000 | 10–25 | 15.2 (4.0) | 4.5 (2.7) | 50 (38: 4–154) | |